Clinical Trials Logo

Clinical Trial Summary

The aim of this prospective longitudinal study is to compare the quality of life of short bowel patients prior to and on teduglutide treatment with a non-treated patient group in a matched-pair design.


Clinical Trial Description

Short bowel syndrome (SBS) is a malabsorptive disorder mostly caused by surgical interventions, which may result in chronic intestinal failure (cIF). The incidence is progressively increasing due to more aggressive surgical and medical approaches. Parenteral nutrition is still the mainstay of treatment for patients with irreversible cIF. New hormonal therapies hold promise by romoting mucosal growth and intestinal absorption and thereby leading to a consequent reduction in parenteral support and symptoms related to large stomal or faecal losses. Outside the typical primary endpoints of cost data, quality of life (QoL) is an important and yet underappreciated consideration of the effectiveness of targeted therapies. In the clinical STEPS trial, Jeppesen et al. have previously shown a significant improvement of the SBS-QoL total score after 24 week treatment with teduglutide longitudinally but could not identify a statistical significance to the placebo group. Accordingly, Chen and colleagues carried out a post hoc analysis of the afore mentioned clinical trial data based on 86 patients and could confirm the results auf Jeppesen et al. Taken together, these clinical trial data did not show a direct benefit of teduglutide treatment on QoL in these patients, while real life data on QoL changes are not available yet. During the release of teduglutide in Germany, the PNLiver trial (DRKS00010993) recruited chronic intestinal failure patients with parenteral nutrition from 2014 till 2019 to evaluate the capability of non-invasive liver function tests in cIF patients in a cross-sectional (n=90) and longitudinal study (n=20. All participants underwent study visits including clinical examination, dynamic liver function assessment, comprehensive blood tests, nutritional status assessment and quality of life assessment (Short Form 36 [SF-36] and SBS-QoL). Therefore, we have a comprehensive data set of a large monocentric cIF cohort prior to teduglutide treatment. Consequently, our unique QoL data from the PNLiver trail enables a followup assessment for an observation period above 24 weeks of patients who were in the meantime exposed to teduglutide in a real life setting. Nevertheless, QoL also tends to improve with longer duration on HPN. Therefore, we are aiming to extend the results with a pairwise matched control group from non teduglutide-treated PNLiver trail patients and collect follow-up data from this group accordingly. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04733066
Study type Observational
Source Charite University, Berlin, Germany
Contact Elisabeth Blüthner, MD
Phone 004930450665209
Email elisabeth.bluethner@charite.de
Status Recruiting
Phase
Start date September 1, 2020
Completion date September 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05635747 - A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
Completed NCT01891279 - Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition? N/A
Completed NCT00930644 - Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS) Phase 3
Completed NCT01696656 - Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency N/A
Completed NCT00910104 - Cholestasis Reversal: Efficacy of IV Fish Oil Phase 2/Phase 3
Completed NCT04981262 - Improved Quality of Life in Children With Intestinal Failure N/A
Completed NCT01930539 - Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp N/A
Recruiting NCT05023382 - A Study of Teduglutide in Japanese People With Short Bowel Syndrome
Terminated NCT00742157 - Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS) Phase 4
Completed NCT04743960 - Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition N/A
Completed NCT03690206 - Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) Phase 3
Terminated NCT02266849 - Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study Phase 3
Completed NCT01306838 - Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy Early Phase 1
Completed NCT01380366 - rHGH and Intestinal Permeability in Intestinal Failure Phase 4
Completed NCT00248573 - Mechanisms of Adaptation in Human Short Bowel Syndrome Phase 1/Phase 2
Withdrawn NCT03371862 - Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) Phase 2
Completed NCT04474743 - Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
Completed NCT00067860 - Diet/Growth Factor Mechanisms of Gut Adaptation Phase 2
Terminated NCT04046328 - Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome Phase 2
Completed NCT04877431 - A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease